Source-grounded facts extracted from INOVIO PHARMACEUTICALS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
INOVIO PHARMACEUTICALS, INC. shareholders approved Approval of amendment and restatement of Amended and Restated 2023 Omnibus Incentive Plan at the 2026-05-20 meeting.
“Proposal 4 : The approval of the amendment and restatement of the Company’s Amended and Restated 2023 Omnibus Incentive Plan as described in the Proxy Statement. The votes were cast as follows: For Against Abstain Broker Non-Votes 21,559,350 1,535,940 484,088 17,091,251”
INOVIO PHARMACEUTICALS, INC. shareholders approved Non-binding advisory approval of compensation of NEOs at the 2026-05-20 meeting.
“Proposal 3 : The approval, on a non-binding advisory basis, of the compensation of the NEOs described in the Proxy Statement. The votes were cast as follows: For Against Abstain Broker Non-Votes 21,500,999 1,607,592 470,787 17,091,251”
INOVIO PHARMACEUTICALS, INC. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-20 meeting.
“Proposal 2 : The ratification of the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows: For Against Abstain Broker Non-Votes 39,329,582 1,198,040 143,007 —”
INOVIO PHARMACEUTICALS, INC. shareholders approved Election of eight nominees as directors at the 2026-05-20 meeting.
“Proposal 1 : The election of the following eight nominees as directors of the Company to serve until the Company’s 2027 Annual Meeting of Stockholders and until their successors are elected. The votes were cast as follows: Name of Director Nominee Votes For Votes Withheld Broker Non-Votes Simon X. Benito 22,312,198 1,267,180 17,091,251 Roger D. Dansey, M.D. 22,480,244 1,099,134 17,091,251 Ann C. Miller, M.D. 22,544,652 1,034,726 17,091,251 Jacqueline E. Shea, Ph.D. 22,560,816 1,018,562 17,091,251 Jay P. Shepard 22,468,210 1,111,168 17,091,251 David B. Weiner, Ph.D. 22,666,881 912,497 17,091,251 Wendy L. Yarno 22,451,874 1,127,504 17,091,251 Lota S. Zoth 22,455,943 1,123,435 17,091,251”
INOVIO PHARMACEUTICALS, INC.: Amendment to bylaws to clarify Chairman role, establish Lead Independent Director, and update order of presiding officers (effective 2026-05-19).
“On May 19, 2026, the board of directors (the “ Board ”) of Inovio Pharmaceuticals, Inc. (the “ Company ”) approved an amendment to the Company’s Amended and Restated bylaws (the “ Bylaws Amendment ”) effective immediately to further enhance the Company’s corporate governance practices by, among other things, (i) clarifying the role of the Chairman of the Board, including that the Chairman shall not be deemed an officer of the corporation unless expressly designated as such by the Board, (ii) establishing the position of Lead Independent Director, including the designation, duties and responsibilities thereof, and requiring the appointment of a Lead Independent Director in the event the Chief Executive Officer also serves as Chairman of the Board and (iii) updating the order of presiding officers at meetings of the Board and stockholders to reflect the foregoing changes.”
INOVIO PHARMACEUTICALS, INC. reported financial results for the three months ended March 31, 2026.
“On May 13, 2026, Inovio Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.”
INOVIO PHARMACEUTICALS, INC. entered into Underwriting Agreement with Piper Sandler & Co. valued at Public offering of 12,500,000 shares of common stock and Series A and Series B warrants with an opti (effective 2026-04-02).
“On April 2, 2026, Inovio Pharmaceuticals, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Piper Sandler & Co., as representative of the several underwriters named therein (collectively, the “ Underwriters ”), relating to the issuance and sale by the Company in a public offering of 12,500,000 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), and accompanying Series A warrants to purchase up to 12,500,000 shares of its Common Stock (or pre-funded warrants, each representing the right to purchase one share of Common Stock at an exercise price of $0.001 (the “ Pre-Funded Warrants ”) in lieu thereof) at an exercise price of $1.40 per share of common stock (or $1.399 per Pre-Funded Warrant) (the “ Series A Warrants ”) and Series B warrants to purchase up to 12,500,000 shares of its Common Stock (or Pre-Funded Warrants in lieu thereof) at an exercise price of $1.40 per share of Common S”
INOVIO PHARMACEUTICALS, INC. reported financial results for the fourth quarter and full year ended December 31, 2025.
“On March 12, 2026, Inovio Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter and full year ended December 31, 2025.”
INOVIO PHARMACEUTICALS, INC. issued up to 13,564,268 shares of warrant for exercise price of $1.75 per share.
“each representing the right to purchase one share of Common Stock at an exercise price of $0.001 (the “Pre-Funded Warrants”) in lieu thereof), and have an exercise price of $1.75 per share (or $1.749 per Pre-Funded Warrant) and would otherwise have expired at 5:00 p.m. New York City time on January 28, 2026, which is 30 days following the Company’s public”
INOVIO PHARMACEUTICALS, INC. amended Series A Warrants (effective 2026-01-27).
“On January 27, 2026, Inovio Pharmaceuticals, Inc. (the “Company”) amended each of its outstanding Series A warrants issued on July 7, 2025 (the “Series A Warrants”) to extend the expiration date”
INOVIO PHARMACEUTICALS, INC. reported financial results for first quarter of 2024.
“On May 13, 2024, Inovio Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended March 31, 2024.”
INOVIO PHARMACEUTICALS, INC. entered into Underwriting Agreement with Oppenheimer & Co. Inc. and Citizens JMP Securities, LLC, as representatives of the several underwriters named therein valued at approximately $33.2 million (effective 2024-04-15).
“On April 15, 2024, Inovio Pharmaceuticals, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Oppenheimer & Co. Inc. and Citizens JMP Securities, LLC, as representatives of the several underwriters named therein (collectively, the “ Underwriters ”), relating to the issuance and sale by the Company in an underwritten registered direct offering (the “ Offering ”) of 2,536,258 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), at a price of $7.693 per share and pre-funded warrants to purchase up to 2,135,477 shares of Common Stock (the “ Pre-Funded Warrants ”) at a price of $7.692 per Pre-Funded Warrant, which represents the per share price for the Shares less the $0.001 per share exercise price for each Pre-Funded Warrant.”
INOVIO PHARMACEUTICALS, INC.: 1-for-12 reverse stock split of common stock effected through certificate of amendment to certificate of incorporation (effective 2024-01-24).
“On January 24, 2024, Inovio Pharmaceuticals, Inc. (the “ Company ”) filed with the Secretary of State of the State of Delaware a certificate of amendment to its certificate of incorporation, as previously amended (the “ Charter Amendment ”) to effect a 1-for-12 reverse stock split of the Company’s common stock (the “ Reverse Stock Split ”). The Reverse Stock Split became effective at 5:00 p.m. Eastern Time on January 24, 2024.”
INOVIO PHARMACEUTICALS, INC. shareholders approved Adjournment Proposal at the 2024-01-12 meeting.
“The votes were cast as follows: For Against Abstain 106,842,257 37,097,854 2,325,862 The Adjournment Proposal was approved.”
INOVIO PHARMACEUTICALS, INC. shareholders approved Reverse Stock Split Proposal at the 2024-01-12 meeting.
“The votes were cast as follows: For Against Abstain 96,534,629 48,857,255 874,089 The Reverse Stock Split Proposal was approved.”
INOVIO PHARMACEUTICALS, INC. reported financial results for third quarter ended September 30, 2023.
“On November 9, 2023, Inovio Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter and nine months ended September 30, 2023.”
INOVIO PHARMACEUTICALS, INC. reported financial results for quarter and six months ended June 30, 2023.
“On August 9, 2023, Inovio Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter and six months ended June 30, 2023.”
INOVIO PHARMACEUTICALS, INC. announced a restructuring with charges of approximately $2.1 million (58 employees).
“On July 31, 2023, Inovio Pharmaceuticals, Inc. (the “ Company ”) committed to and communicated a corporate reorganization plan, including a reduction in force of 58 employees (the “ Reduction ”), representing approximately 30% of its full-time employees. The Company expects to incur a one-time pre-tax charge of approximately $2.1 million in the third quarter of 2023 related to the Reduction, consisting primarily of one-time severance payments upon termination, continued healthcare benefits for a specific period of time, and outplacement services.”
INOVIO PHARMACEUTICALS, INC. shareholders approved Approval of 2023 Plan (equity incentive plan) at the 2023-05-16 meeting.
“Proposal 5 : The approval of the 2023 Plan. The votes were cast as follows: For Against Abstain Broker Non-Votes 82,275,834 10,297,565 1,300,462 67,558,089”
INOVIO PHARMACEUTICALS, INC. shareholders approved Advisory vote on preferred frequency of solicitation of advisory stockholder approval of executive compensation at the 2023-05-16 meeting.
“Proposal 4 : The approval, on a non-binding advisory basis, of the preferred frequency of solicitation of advisory stockholder approval of executive compensation. The votes were cast as follows: 1 year 2 years 3 years Abstain Broker Non-Votes 89,231,218 620,214 2,228,531 1,793,898 67,558,089”
INOVIO PHARMACEUTICALS, INC. shareholders approved Advisory vote on compensation of named executive officers at the 2023-05-16 meeting.
“Proposal 3 : The approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers described in the Proxy Statement. The votes were cast as follows: For Against Abstain Broker Non-Votes 60,418,592 32,244,808 1,210,461 67,558,089”
INOVIO PHARMACEUTICALS, INC. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-05-16 meeting.
“Proposal 2 : The ratification of the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The votes were cast as follows: For Against Abstain Broker Non-Votes 155,603,443 4,041,813 1,786,694 0”
INOVIO PHARMACEUTICALS, INC. shareholders approved Election of eight nominees as directors to serve until 2024 Annual Meeting at the 2023-05-16 meeting.
“Proposal 1 : The election of the following eight nominees as directors of the Company to serve until the Company’s 2024 Annual Meeting of Stockholders and until their successors are elected. The votes were cast as follows: Name of Director Nominee Votes For Votes Withheld Broker Non-Votes Simon X. Benito 79,621,809 14,252,052 67,558,089 Roger D. Dansey, M.D. 88,240,426 5,633,435 67,558,089 Ann C. Miller, M.D. 85,733,147 8,140,714 67,558,089 Jacqueline E. Shea, Ph.D. 87,597,826 6,276,035 67,558,089 Jay P. Shepard 85,224,476 8,649,385 67,558,089 David B. Weiner, Ph.D. 89,390,687 4,483,174 67,558,089 Wendy L. Yarno 82,108,386 11,765,475 67,558,089 Lota S. Zoth 57,425,572 36,448,289 67,558,089”
INOVIO PHARMACEUTICALS, INC. reported financial results for the quarter ended March 31, 2023.
“On May 10, 2023, Inovio Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended March 31, 2023.”
INOVIO PHARMACEUTICALS, INC. reported financial results for the quarter and year ended December 31, 2022.
“On March 1, 2023, Inovio Pharmaceuticals, Inc. (the " Company ") issued a press release announcing its financial results for the quarter and year ended December 31, 2022.”
INOVIO PHARMACEUTICALS, INC. announced a restructuring with charges of approximately $1.1 million (approximately 24 employees).
“On January 31, 2023, Inovio Pharmaceuticals, Inc. (the “ Company ”) committed to and communicated a corporate reorganization plan, including a reduction in force (the “ Reduction ”). The purpose of the Reduction is to decrease expenses and maintain a streamlined organization to support key clinical programs that are expected to drive long-term growth. As part of the Reduction, the Company has reduced its overall headcount by approximately 24 employees, which represents 11% of its full-time employees. Along with other planned cost-saving measures, the Reduction is expected to provide annual savings of approximately $4.3 million. The Company expects to incur a one-time pre-tax charge of approximately $1.1 million in the first quarter of 2023 related to the Reduction”
INOVIO PHARMACEUTICALS, INC. reported third quarter and nine months ended September 30, 2022 results: revenue $9.2 million, net income $37.8 million, or $0.15 per basic and diluted share, EPS $0.15 per basic and diluted share.
“vesting, and conversion, as applicable, of its outstanding options, restricted stock units, convertible preferred stock, and convertible debt. INOVIO reported total revenue of $9.2 million for the three months ended, September 30, 2022, compared to $292,000 for the same period in 2021. The increase in revenue resulted from the fulfillment of obligations under its”
Jacqueline E. Shea was appointed as President and Chief Executive Officer at INOVIO PHARMACEUTICALS, INC..
“the Board appointed Dr. Jacqueline Shea, currently the Company’s Chief Operating Officer, to serve as the Company’s President and Chief Executive Officer”
J. Joseph Kim resigned as President, Chief Executive Officer and Director at INOVIO PHARMACEUTICALS, INC..
“J. Joseph Kim, President and Chief Executive Officer of the Company, resigned from those positions and also resigned as a member of the Company’s Board of Directors”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.